Efficacy of Metamizole Versus Ibuprofen and a Short Educational Intervention Versus Standard Care in Acute Low Back Pain
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The EMISI trial is a randomized, double blind, controlled trial (RCT) using a factorial
design in patients with a new low back pain episode. The study aims to assess (A) whether
metamizole, a non-opioid drug approved in Switzerland for pain treatment, is non-inferior to
ibuprofen in a new episode of acute or subacute LBP and (B) whether a short educational
intervention including evidence-based patient information is superior to usual care alone.
Despite its increased use, the role of metamizole for the treatment of LBP is unclear and has
so far not been systematically studied.